Back to top
more

DaVita (DVA)

(Real Time Quote from BATS)

$162.05 USD

162.05
289,268

-2.17 (-1.32%)

Updated Sep 18, 2024 01:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (49 out of 250)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

NextGen (NXGN) Q4 Earnings Top Estimates, Revenues Surge Y/Y

by Zacks Equity Research

NextGen's (NXGN) fourth-quarter fiscal 2023 results reflect strength in both its revenue sources.

3 Reasons to Retain Masimo (MASI) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.

Shockwave Medical (SWAV) Launches IVL Catheter in Select Markets

by Zacks Equity Research

Shockwave Medical's (SWAV) latest commercial availability and the patient enrollment in its study are expected to serve a wider patient pool.

Here's Why You Should Hold Molina (MOH) in Your Portfolio

by Zacks Equity Research

Molina's (MOH) inorganic growth activities, financial flexibility and well-performing Medicaid and Medicare segments poise it for growth.

Earnings Estimates Rising for DaVita HealthCare (DVA): Will It Gain?

by Zacks Equity Research

DaVita HealthCare (DVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Shaun Pruitt headshot

2 Top-Rated Medical Stocks to Buy After Earnings

by Shaun Pruitt

As we round out this week's earnings lineup, a few healthcare companies are standing out after topping their quarterly earnings expectations.

Is Addus HomeCare (ADUS) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

DVA vs. CHE: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

DVA vs. CHE: Which Stock Is the Better Value Option?

DaVita HealthCare (DVA)'s Technical Outlook is Bright After Key Golden Cross

by Zacks Equity Research

Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?

DaVita (DVA) Tops Q1 Earnings Estimates, Ups FY23 EPS View

by Zacks Equity Research

DaVita's (DVA) robust revenues in both segments drive its first-quarter performance.

DaVita HealthCare (DVA) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

DaVita HealthCare (DVA) delivered earnings and revenue surprises of 46.30% and 1.57%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

The Pennant Group, Inc. (PNTG) Misses Q1 Earnings Estimates

by Zacks Equity Research

The Pennant Group, Inc. (PNTG) delivered earnings and revenue surprises of -13.33% and 3.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

DaVita (DVA) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

High labor costs and inflationary pressures are likely to have weighed on DaVita's (DVA) first-quarter top line.

U.S. Physical Therapy (USPH) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

U.S. Physical Therapy (USPH) delivered earnings and revenue surprises of 13.46% and 6.19%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

3 Reasons to Retain DaVita (DVA) Stock in Your Portfolio

by Zacks Equity Research

Investors remain optimistic about DaVita (DVA) due to the strength in its DaVita Kidney Care.

DaVita (DVA) Q4 Earnings Beat Estimates, Margins Down

by Zacks Equity Research

Despite DaVita's (DVA) robust revenues in its Other segment, its overall Q4 performance was soft.

DaVita HealthCare (DVA) Q4 Earnings Beat Estimates

by Zacks Equity Research

DaVita HealthCare (DVA) delivered earnings and revenue surprises of 26.14% and 0.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Debanjana Dey headshot

MedTech Stocks' Q4 Earnings on Feb 22: FMS, GKOS & More

by Debanjana Dey

MedTech companies' Q4 results are likely to reflect strength in customer demand. Let's see how FMS, GKOS, MMSI and DVA are placed ahead of their earnings releases.

Addus HomeCare (ADUS) Reports Next Week: What to Expect

by Zacks Equity Research

Addus HomeCare (ADUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

DaVita (DVA) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

High labor costs, along with inflationary pressures, are likely to have weighed on DaVita's (DVA) fourth-quarter top line.

Earnings Preview: DaVita HealthCare (DVA) Q4 Earnings Expected to Decline

by Zacks Equity Research

DaVita HealthCare (DVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Strength Seen in Oak Street Health, Inc. (OSH): Can Its 29.7% Jump Turn into More Strength?

by Zacks Equity Research

Oak Street Health, Inc. (OSH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

U.S. Physical Therapy (USPH) Soars 3.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

U.S. Physical Therapy (USPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Here's Why You Should Retain DaVita (DVA) Stock for Now

by Zacks Equity Research

Investors remain optimistic about DaVita (DVA) due to the strength in its DaVita Kidney Care.

Is the Options Market Predicting a Spike in DaVita (DVA) Stock?

by Zacks Equity Research

Investors need to pay close attention to DaVita (DVA) stock based on the movements in the options market lately.